Idenix Pharmaceuticals Inc., of Cambridge, Mass., reported data from a Phase I trial of IDX719, an NS5A inhibitor to treat hepatitis C virus (HCV) infection, demonstrating potent pan-genotypic antiviral activity with single doses. The study, initiated in January, evaluated the safety, pharmacokinetics and food effect of IDX719 in 40 healthy volunteers at single doses ranging from 5 mg to 100 mg. All doses were well tolerated, and pharmacokinetic data supported once-daily dosing in future studies.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter